Axsome Therapeutics Receives Positive Ratings and Maintains Moderate Buy Consensus
As of September 25, 2023, Axsome Therapeutics (NASDAQ: AXSM) has received evaluations from 8 analysts who have provided their 12-month ...
Tag: AXSM
Optimistic Outlook for Axsome Therapeutics Analysts Predict Promising Future
As of September 25, 2023, various reputable sources have expressed an optimistic view on Axsome Therapeutics, a pharmaceutical company. These ...
Aristotle Capital Boston LLC Increases Stake in AZZ Inc. as Company Faces Opportunities and Challenges in a Shifting Market
On September 12, 2023, Aristotle Capital Boston LLC announced that it has increased its stake in AZZ Inc. (NYSE:AZZ) by ...
BVF Inc. IL Increases Stake in Axsome Therapeutics: Demonstrates Confidence in CNS Disorder Treatments
BVF Inc. IL, an investment firm, has recently increased its stake in Axsome Therapeutics, Inc. by 21.4% during the first ...
Significant Increase in Holdings: & Fmr LLC Shows Confidence in Axsome Therapeutics’ Potential in CNS Disorders Market
On September 5, 2023, it was reported that & Fmr LLC had significantly increased its holdings in Axsome Therapeutics, Inc. ...
Genuine Parts: Decrease in Stake by Dimensional Fund Advisors LP Raises Questions about Stock Performance and Growth Prospects
On September 5, 2023, Dimensional Fund Advisors LP announced a decrease in its position in Genuine Parts (NYSE:GPC) by 0.6% ...
ExodusPoint Capital Management Acquires Stake in AvidXchange Holdings, Inc.: Analysis of Recent Transactions and Financial Performance
On September 4, 2023, it was reported that ExodusPoint Capital Management LP has acquired a new stake in AvidXchange Holdings, ...
Bank of New York Mellon Corp Reduces Stake in Axsome Therapeutics, Inc. by 2.6%
September 4, 2023 - Bank of New York Mellon Corp has reported a decrease in its stake in Axsome Therapeutics, ...
Axsome Therapeutics Receives Moderate Buy Consensus Recommendation and Attracts Interest from Institutional Investors
Axsome Therapeutics, Inc. (NASDAQ:AXSM) has received a "Moderate Buy" consensus recommendation from twelve analysts, as reported by Bloomberg on September ...
Pearl River Capital LLC Increases Stake in Axsome Therapeutics as Company Shows Positive Earnings and Growth Potential in Biopharmaceutical Industry
On September 1, 2023, it was announced that Pearl River Capital LLC has increased its stake in Axsome Therapeutics, Inc. ...